Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study
Launched by UNIVERSITY OF DUNDEE · Sep 23, 2013
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
The ALTERED trial is a randomised, double blinded, placebo controlled multi-centre study conducted in NHS Tayside, NHS Ayrshire \& Arran \& NHS Greater Glasgow \& Clyde to compare allopurinol (dose to be confirmed from dose escalation study noted above) at either, 100mg, 200mg, 250mg, 300mg or 350mg to placebo.
Patients will be enrolled in this trial for a period of between 12 to 13 months.
At screening visit an initial history and clinical examination will be performed. Participants will then undergo an echocardiogram to ensure no significant heart failure unless they have had an ECHO in...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • aged 18 years or over
- • end stage renal disease (CKD stage 5 eGFR \<15ml/min /1.73m2)
- • been on haemodialysis for at least 3 months.
- Exclusion Criteria:
- • Known heart failure
- • Left Ventricular Ejection Fraction \<45%,
- • active gout
- • severe hepatic disease
- • or on azathioprine, 6 mercaptopurine, theophylline.
- • malignancy or other life threatening diseases,
- • pregnant or lactating women
- • any contraindication to MRI (claustrophobia, metal implants).
- • with a planned (relative) kidney transplant,
- • Patients who have participated in any other clinical trial within the previous 30 days will be excluded.
- • Patients who are unable to give informed consent will also be excluded from this trial.
- • Any other considered by a study physician to be inappropriate for inclusion
About University Of Dundee
The University of Dundee is a leading research institution in the United Kingdom, renowned for its commitment to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on interdisciplinary collaboration, the university leverages its expertise in biomedical sciences, medicine, and health technology to address pressing health challenges. The University of Dundee fosters an environment of academic excellence, driving the development of novel therapies and interventions that aim to improve patient outcomes. Its state-of-the-art facilities and dedication to ethical research practices ensure the highest standards of clinical trial management and oversight.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Glasgow, La, United Kingdom
Dundee, Tayside, United Kingdom
Crosshouse, , United Kingdom
Patients applied
Trial Officials
Allan D Struthers, BSc, MD, FRCP, FESC, FRSE
Study Director
Centre for Cadiovascular Medicine, University of Dundee
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials